These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9746382)

  • 1. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England.
    Wilton LV; Pearce GL; Martin RM; Mackay FJ; Mann RD
    Br J Obstet Gynaecol; 1998 Aug; 105(8):882-9. PubMed ID: 9746382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study.
    McKenna K; Koren G; Tetelbaum M; Wilton L; Shakir S; Diav-Citrin O; Levinson A; Zipursky RB; Einarson A
    J Clin Psychiatry; 2005 Apr; 66(4):444-9; quiz 546. PubMed ID: 15816786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations.
    Huybrechts KF; Hernández-Díaz S; Patorno E; Desai RJ; Mogun H; Dejene SZ; Cohen JM; Panchaud A; Cohen L; Bateman BT
    JAMA Psychiatry; 2016 Sep; 73(9):938-46. PubMed ID: 27540849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study.
    Ban L; West J; Gibson JE; Fiaschi L; Sokal R; Doyle P; Hubbard R; Smeeth L; Tata LJ
    PLoS One; 2014; 9(6):e100996. PubMed ID: 24963627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
    Clowse MEB; Scheuerle AE; Chambers C; Afzali A; Kimball AB; Cush JJ; Cooney M; Shaughnessy L; Vanderkelen M; Förger F
    Arthritis Rheumatol; 2018 Sep; 70(9):1399-1407. PubMed ID: 29623679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes.
    Ruigómez A; García Rodríguez LA; Cattaruzzi C; Troncon MG; Agostinis L; Wallander MA; Johansson S
    Am J Epidemiol; 1999 Sep; 150(5):476-81. PubMed ID: 10472947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer-generation antiepileptic drugs and the risk of major birth defects.
    Mølgaard-Nielsen D; Hviid A
    JAMA; 2011 May; 305(19):1996-2002. PubMed ID: 21586715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure to Infliximab During Pregnancy: Post-Marketing Experience.
    Geldhof A; Slater J; Clark M; Chandran U; Coppola D
    Drug Saf; 2020 Feb; 43(2):147-161. PubMed ID: 31677004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid monotherapy in pregnancy and major congenital malformations.
    Jentink J; Loane MA; Dolk H; Barisic I; Garne E; Morris JK; de Jong-van den Berg LT;
    N Engl J Med; 2010 Jun; 362(23):2185-93. PubMed ID: 20558369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.
    Ephross SA; Sinclair SM
    Headache; 2014; 54(7):1158-72. PubMed ID: 24805878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure to golimumab during pregnancy: Results from the Company's global safety database.
    Otero-Lobato M; Adeyemo A; Higley M; Lomax KG; Geldhof A; Esslinger S
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1240. PubMed ID: 38970433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued occurrence of Accutane-exposed pregnancies.
    Honein MA; Paulozzi LJ; Erickson JD
    Teratology; 2001 Sep; 64(3):142-7. PubMed ID: 11514944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of congenital anomalies in pregnant users of statin drugs.
    Ofori B; Rey E; Bérard A
    Br J Clin Pharmacol; 2007 Oct; 64(4):496-509. PubMed ID: 17506782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study.
    Bateman BT; Hernandez-Diaz S; Straub L; Zhu Y; Gray KJ; Desai RJ; Mogun H; Gautam N; Huybrechts KF
    BMJ; 2021 Feb; 372():n102. PubMed ID: 33568363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin.
    Pollack PS; Shields KE; Burnett DM; Osborne MJ; Cunningham ML; Stepanavage ME
    Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):888-96. PubMed ID: 16163683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescriptions filled during pregnancy for drugs with the potential of fetal harm.
    Kulaga S; Zargarzadeh AH; Bérard A
    BJOG; 2009 Dec; 116(13):1788-95. PubMed ID: 19832828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of metoclopramide use in the first trimester of pregnancy.
    Matok I; Gorodischer R; Koren G; Sheiner E; Wiznitzer A; Levy A
    N Engl J Med; 2009 Jun; 360(24):2528-35. PubMed ID: 19516033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fetal Exposure to Montelukast and Congenital Anomalies: A Population Based Study in Denmark.
    Cavero-Carbonell C; Vinkel-Hansen A; Rabanque-Hernández MJ; Martos C; Garne E
    Birth Defects Res; 2017 Apr; 109(6):452-459. PubMed ID: 28398707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy.
    Daniel S; Matok I; Gorodischer R; Koren G; Uziel E; Wiznitzer A; Levy A
    J Rheumatol; 2012 Nov; 39(11):2163-9. PubMed ID: 22984274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incidence of congenital defects in the children of mothers who used medications in the first trimester of pregnancy in the Czech Republic 1996-2001].
    Sípek A; Gregor V; Velebil P; Horácek J; Masátová D; Svĕtnicová K
    Ceska Gynekol; 2003 Nov; 68(6):401-19. PubMed ID: 15042851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.